Observational / CohortiVNSn = 14

Neuroimmune Modulation for Drug-Refractory Rheumatoid Arthritis: Long-Term Safety and Efficacy in Patients Enrolled in a Pilot Vagus Nerve Stimulation Study

Gaylis NB, Sikes D, Kivitz A, Horowitz DL, Evangelista M, Levine YA, Chernoff D

Rheumatology and Therapy · 2025

Key finding

In a 36-month open-label extension of an implanted VNS pilot, 64% of completers maintained a clinically meaningful CDAI response with sustained safety in drug-refractory RA.

Condition
Rheumatoid Arthritis
Stimulation
iVNS
Evidence tier
Observational / Cohort
Participants
14
View on DOI

Cite this study

Gaylis, N. B., Sikes, D., Kivitz, A., Horowitz, D. L., Evangelista, M., Levine, Y. A., & Chernoff, D. (2025). Neuroimmune Modulation for Drug-Refractory Rheumatoid Arthritis: Long-Term Safety and Efficacy in Patients Enrolled in a Pilot Vagus Nerve Stimulation Study. Rheumatology and Therapy, 12(6), 1125-1136. https://doi.org/10.1007/s40744-025-00798-y

Related studies in Rheumatoid Arthritis

Summary by Vagus Research. Always consult the primary source for the authoritative record.

Stay Current with the Research

Join researchers and practitioners exploring the science of vagus nerve stimulation. Receive curated research summaries and evidence updates.

No spam. Unsubscribe at any time. We respect your privacy.